1. Home
  2. BRIA vs AVTE Comparison

BRIA vs AVTE Comparison

Compare BRIA & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • AVTE
  • Stock Information
  • Founded
  • BRIA 2011
  • AVTE 2018
  • Country
  • BRIA Singapore
  • AVTE United States
  • Employees
  • BRIA N/A
  • AVTE N/A
  • Industry
  • BRIA
  • AVTE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • AVTE Health Care
  • Exchange
  • BRIA NYSE
  • AVTE Nasdaq
  • Market Cap
  • BRIA 73.0M
  • AVTE 72.5M
  • IPO Year
  • BRIA 2024
  • AVTE 2021
  • Fundamental
  • Price
  • BRIA $1.99
  • AVTE $2.51
  • Analyst Decision
  • BRIA
  • AVTE Hold
  • Analyst Count
  • BRIA 0
  • AVTE 7
  • Target Price
  • BRIA N/A
  • AVTE $11.75
  • AVG Volume (30 Days)
  • BRIA 25.5K
  • AVTE 62.3K
  • Earning Date
  • BRIA 05-15-2025
  • AVTE 03-27-2025
  • Dividend Yield
  • BRIA N/A
  • AVTE N/A
  • EPS Growth
  • BRIA N/A
  • AVTE N/A
  • EPS
  • BRIA 92.24
  • AVTE N/A
  • Revenue
  • BRIA $55,755,669.00
  • AVTE N/A
  • Revenue This Year
  • BRIA N/A
  • AVTE N/A
  • Revenue Next Year
  • BRIA N/A
  • AVTE N/A
  • P/E Ratio
  • BRIA $0.02
  • AVTE N/A
  • Revenue Growth
  • BRIA 8.03
  • AVTE N/A
  • 52 Week Low
  • BRIA $1.87
  • AVTE $1.25
  • 52 Week High
  • BRIA $4.38
  • AVTE $32.42
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • AVTE 52.00
  • Support Level
  • BRIA N/A
  • AVTE $2.44
  • Resistance Level
  • BRIA N/A
  • AVTE $2.56
  • Average True Range (ATR)
  • BRIA 0.00
  • AVTE 0.09
  • MACD
  • BRIA 0.00
  • AVTE 0.00
  • Stochastic Oscillator
  • BRIA 0.00
  • AVTE 77.14

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About AVTE Aerovate Therapeutics Inc.

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Share on Social Networks: